Aroa Biosurgery Limited (ASX:ARX)
Australia · Delayed Price · Currency is AUD | Market Cap | 186.79M +23.1% |
| Revenue (ttm) | 79.26M +18.4% |
| Net Income | -1.60M |
| EPS | -0.00 |
| Shares Out | 345.90M |
| PE Ratio | n/a |
| Forward PE | 53.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 216,680 |
| Average Volume | 138,318 |
| Open | 0.5350 |
| Previous Close | 0.5400 |
| Day's Range | 0.5350 - 0.5650 |
| 52-Week Range | 0.3750 - 0.8000 |
| Beta | 0.81 |
| RSI | 46.69 |
| Earnings Date | May 31, 2026 |
About Aroa Biosurgery
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that de... [Read more]
Financial Performance
In fiscal year 2025, Aroa Biosurgery's revenue was 84.70 million, an increase of 22.63% compared to the previous year's 69.07 million. Losses were -3.81 million, -64.12% less than in 2024.
Financial numbers in NZD Financial StatementsNews
Aroa Biosurgery Earnings Call Transcript: Q3 2026
Clinical and commercial momentum is strong, with Myriad outperforming in trauma and Symphony poised to benefit from US reimbursement changes. FY26 revenue and EBITDA are tracking toward the upper end of guidance, with ongoing profitability and positive cash flow.
Aroa Biosurgery Earnings Call Transcript: H1 2026
Revenue grew 13% YoY to $44.9M with positive EBITDA and strong cash flow. Myriad sales surged 33%, and Tela Bio expanded its commercial team and product pipeline. CMS reimbursement changes may disrupt competitors, creating new opportunities.
Aroa Biosurgery Earnings Call Transcript: Q2 2026
Achieved a fourth consecutive quarter of positive cash flow, with record Myriad sales up over 30% year-over-year and strong cash reserves. Guidance for revenue and EBITDA was reiterated, while U.S. reimbursement changes and tariffs present manageable risks.
Aroa Biosurgery Transcript: AGM 2025
The meeting reviewed strong 23% growth, margin improvements, and positive cash flow, with continued investment in product development and international expansion. No dividend is planned as focus remains on reinvestment. Key risks include U.S. tariffs and TELA Bio's performance.
Aroa Biosurgery Earnings Call Transcript: Q1 2026
Sales and cash flow tracked in line with expectations, with strong Myriad and TELA Bio performance. Guidance for revenue and EBITDA was reaffirmed, and CMS reimbursement proposals could benefit Symphony if enacted.
Aroa Biosurgery Earnings Call Transcript: H2 2025
Revenue grew 23% to AUD 84.7 million, with first positive normalized EBITDA of AUD 4.2 million and strong cash position. Myriad drove growth, while guidance for FY 2026 targets 10–20% revenue increase and continued profitability.
Aroa Biosurgery Earnings Call Transcript: Q4 2025
Delivered two consecutive quarters of positive cash flow and reaffirmed full-year revenue and EBITDA guidance. Myriad and TELA Bio segments showed strong sales growth, with a robust cash position and ongoing operational improvements.
Aroa Biosurgery Earnings Call Transcript: Q3 2025
Positive operating cash flow and strong Myriad sales drove improved profitability, despite softer TELA Bio partnership sales. Updated guidance reflects revenue growth, ongoing US expansion, and robust clinical outcomes, with Myriad showing low infection rates and significant cost savings.
Aroa Biosurgery Earnings Call Transcript: H1 2025
Strong first-half revenue growth, high gross margins, and robust sales momentum for Myriad and TELA Bio support reaffirmed full-year guidance. Clinical evidence and new product launches underpin continued expansion in a large addressable market.
Aroa Biosurgery Earnings Call Transcript: Q2 2025
Net cash flow from operations improved significantly, with expectations for positive operating cash flow in the second half. Myriad and OviTex drive growth, supported by strong clinical data and regulatory approvals, while guidance for FY 2025 remains unchanged.
Aroa Biosurgery Earnings Call Transcript: Q1 2025
Quarterly cash receipts reached AUD 17.8 million with a strong cash position and robust growth in Myriad and OviTex product lines. Revenue and EBITDA guidance were maintained, with significant clinical and commercial momentum and expanding global reach.
Aroa Biosurgery Transcript: AGM 2024
The meeting reviewed strong Myriad sales growth, ongoing clinical studies, and strategic expansion, while addressing challenges in market uptake and profitability. Board elections and resolutions proceeded smoothly, with shareholder engagement on humanitarian and market access topics.